{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,22]],"date-time":"2026-09-22T16:39:29Z","timestamp":1790095169028,"version":"4.0.1"},"reference-count":30,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2020,1,31]],"date-time":"2020-01-31T00:00:00Z","timestamp":1580428800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2020,1,31]],"date-time":"2020-01-31T00:00:00Z","timestamp":1580428800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/100001695","name":"International Waldenstrom's Macroglobulinemia Foundation","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100001695","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100005189","name":"Leukemia and Lymphoma Society","doi-asserted-by":"publisher","award":["R6507-18"],"award-info":[{"award-number":["R6507-18"]}],"id":[{"id":"10.13039\/100005189","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Blood Cancer J."],"abstract":"<jats:title>Abstract<\/jats:title><jats:p>Activating MYD88 mutations promote pro-survival signaling through BTK and HCK, both targets of ibrutinib. Despite high response rates, complete responses to ibrutinib are lacking, and other MYD88 triggered pro-survival pathways may contribute to primary drug resistance. B-cell receptor (BCR) signaling has been observed in lymphomas driven by mutated MYD88, even without activating the BCR pathway mutations. We identified activated SYK (p-SYK), a component of BCR in complex with MYD88 in <jats:italic>MYD88<\/jats:italic>-mutated WM and ABC DLBCL lymphoma cells. Confocal microscopy confirmed co-localization of MYD88 with SYK in <jats:italic>MYD88<\/jats:italic>-mutated cells. Knockdown of MYD88 or use of a MYD88 signaling inhibitor abrogated SYK activation, while expression of mutated but not wild-type <jats:italic>MYD88<\/jats:italic> amplified p-SYK in <jats:italic>MYD88<\/jats:italic>-mutated and wild-type lymphoma cells. Knockdown of SYK or use of inhibitors targeting SYK blocked p-STAT3 and p-AKT signaling in <jats:italic>MYD88<\/jats:italic>-mutated cells. Cell viability analysis showed that combining ibrutinib and SYK inhibitors triggered synthetic killing of <jats:italic>MYD88<\/jats:italic>-mutated lymphoma cells. Our findings extend the spectrum of mutated <jats:italic>MYD88<\/jats:italic> pro-survival signaling to include SYK directed BCR cross talk in <jats:italic>MYD88<\/jats:italic>-mutated lymphomas. Targeting SYK in combination with ibrutinib produces synthetic lethality, providing a framework for the clinical investigation of ibrutinib with SYK inhibitors in <jats:italic>MYD88<\/jats:italic>-mutated lymphomas.<\/jats:p>","DOI":"10.1038\/s41408-020-0277-6","type":"journal-article","created":{"date-parts":[[2020,1,31]],"date-time":"2020-01-31T16:04:00Z","timestamp":1580486640000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":48,"title":["SYK is activated by mutated MYD88 and drives pro-survival signaling in MYD88 driven B-cell lymphomas"],"prefix":"10.1038","volume":"10","author":[{"given":"Manit","family":"Munshi","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xia","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jiaji G.","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lian","family":"Xu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nickolas","family":"Tsakmaklis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maria G.","family":"Demos","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amanda","family":"Kofides","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maria Luisa","family":"Guerrera","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cristina","family":"Jimenez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gloria G.","family":"Chan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1689-1691","authenticated-orcid":false,"given":"Zachary R.","family":"Hunter","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M. Lia","family":"Palomba","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kimon V.","family":"Argyropoulos","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kirsten","family":"Meid","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrew","family":"Keezer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joshua","family":"Gustine","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Toni","family":"Dubeau","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9490-7532","authenticated-orcid":false,"given":"Jorge J.","family":"Castillo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christopher J.","family":"Patterson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jinhua","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sara J.","family":"Buhrlage","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nathanael S.","family":"Gray","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Steven P.","family":"Treon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Guang","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2020,1,31]]},"reference":[{"key":"277_CR1","doi-asserted-by":"publisher","first-page":"826","DOI":"10.1056\/NEJMoa1200710","volume":"367","author":"SP Treon","year":"2012","unstructured":"Treon, S. P. et al. MYD88 L265P somatic mutation in Waldenstrom\u2019s macroglobulinemia. N. Engl. J. Med. 367, 826\u2013833 (2012).","journal-title":"N. Engl. J. Med."},{"key":"277_CR2","doi-asserted-by":"publisher","first-page":"115","DOI":"10.1038\/nature09671","volume":"470","author":"VN Ngo","year":"2011","unstructured":"Ngo, V. N. et al. Oncogenically active MYD88 mutations in human lymphoma. Nature 470, 115\u2013119 (2011).","journal-title":"Nature"},{"key":"277_CR3","doi-asserted-by":"publisher","first-page":"30210","DOI":"10.1074\/jbc.M113.490946","volume":"288","author":"M Loiarro","year":"2013","unstructured":"Loiarro, M. et al. Mutational analysis identifies residues crucial for homodimerization of myeloid differentiation factor 88 (MyD88) and for its function in immune cells. J. Biol. Chem. 288, 30210\u201330222 (2013).","journal-title":"J. Biol. Chem."},{"key":"277_CR4","doi-asserted-by":"publisher","first-page":"3896","DOI":"10.1182\/blood-2014-05-573188","volume":"124","author":"M Avbelj","year":"2014","unstructured":"Avbelj, M. et al. Activation of lymphoma-associated MyD88 mutations via allostery-induced TIR-domain oligomerization. Blood 124, 3896\u20133904 (2014).","journal-title":"Blood"},{"key":"277_CR5","doi-asserted-by":"publisher","first-page":"1222","DOI":"10.1182\/blood-2012-12-475111","volume":"122","author":"G Yang","year":"2013","unstructured":"Yang, G. et al. A mutation in MYD88 (L265P) supports the survival of lymphoplasmacytic cells by activation of Bruton tyrosine kinase in Waldenstrom macroglobulinemia. Blood 122, 1222\u20131232 (2013).","journal-title":"Blood"},{"key":"277_CR6","doi-asserted-by":"publisher","first-page":"3237","DOI":"10.1182\/blood-2016-01-695098","volume":"127","author":"G Yang","year":"2016","unstructured":"Yang, G. et al. HCK is a survival determinant transactivated by mutated MYD88, and a direct target of ibrutinib. Blood 127, 3237\u20133252 (2016).","journal-title":"Blood"},{"key":"277_CR7","doi-asserted-by":"publisher","first-page":"1430","DOI":"10.1056\/NEJMoa1501548","volume":"372","author":"SP Treon","year":"2015","unstructured":"Treon, S. P. et al. Ibrutinib in previously treated Waldenstrom\u2019s macroglobulinemia. N. Engl. J. Med. 372, 1430\u20131440 (2015).","journal-title":"N. Engl. J. Med."},{"key":"277_CR8","doi-asserted-by":"publisher","first-page":"922","DOI":"10.1038\/nm.3884","volume":"21","author":"WH Wilson","year":"2015","unstructured":"Wilson, W. H. et al. Targeting B cell receptor signaling with ibrutinib in diffuse large B cell lymphoma. Nat. Med. 21, 922\u2013926 (2015).","journal-title":"Nat. Med."},{"key":"277_CR9","doi-asserted-by":"publisher","first-page":"1018","DOI":"10.1158\/2159-8290.CD-17-0613","volume":"7","author":"C Grommes","year":"2017","unstructured":"Grommes, C. et al. Ibrutinib unmasks critical role of bruton tyrosine kinase in primary CNS lymphoma. Cancer Discov. 7, 1018\u20131029 (2017).","journal-title":"Cancer Discov."},{"key":"277_CR10","doi-asserted-by":"publisher","first-page":"833","DOI":"10.1016\/j.ccell.2017.04.012","volume":"31","author":"MS Lionakis","year":"2017","unstructured":"Lionakis, M. S. et al. Inhibition of B cell receptor signaling by ibrutinib in primary CNS lymphoma. Cancer Cell 31, 833\u2013843 (2017).","journal-title":"Cancer Cell"},{"key":"277_CR11","doi-asserted-by":"publisher","first-page":"2141","DOI":"10.3109\/10428194.2014.979413","volume":"56","author":"S Yamada","year":"2015","unstructured":"Yamada, S., Ishida, Y., Matsuno, A. & Yamazaki, K. Primary diffuse large B-cell lymphomas of central nervous system exhibit remarkably high prevalence of oncogenic MYD88 and CD79B mutations. Leuk Lymphoma 56, 2141\u20132145 (2015).","journal-title":"Leuk Lymphoma"},{"key":"277_CR12","doi-asserted-by":"publisher","first-page":"2759","DOI":"10.1084\/jem.20161454","volume":"214","author":"JQ Wang","year":"2017","unstructured":"Wang, J. Q. et al. Synergistic cooperation and crosstalk between MYD88(L265P) and mutations that dysregulate CD79B and surface IgM. J Exp Med. 214, 2759\u20132776 (2017).","journal-title":"J Exp Med."},{"key":"277_CR13","doi-asserted-by":"publisher","first-page":"1637","DOI":"10.1182\/blood-2013-09-525808","volume":"123","author":"ZR Hunter","year":"2014","unstructured":"Hunter, Z. R. et al. The genomic landscape of Waldenstrom macroglobulinemia is characterized by highly recurring MYD88 and WHIM-like CXCR4 mutations, and small somatic deletions associated with B-cell lymphomagenesis. Blood 123, 1637\u20131646 (2014).","journal-title":"Blood"},{"key":"277_CR14","doi-asserted-by":"publisher","first-page":"1480","DOI":"10.1158\/1078-0432.CCR-15-0646","volume":"22","author":"S Poulain","year":"2016","unstructured":"Poulain, S. et al. Genomic landscape of CXCR4 mutations in Waldenstr\u00f6m macroglobulinemia. Clin. Cancer Res. 22, 1480\u20131488 (2016).","journal-title":"Clin. Cancer Res."},{"key":"277_CR15","doi-asserted-by":"publisher","first-page":"2077","DOI":"10.3324\/haematol.2017.172718","volume":"102","author":"M Varettoni","year":"2017","unstructured":"Varettoni, M. et al. Pattern of somatic mutations in patients with Waldenstr\u00f6m macroglobulinemia or IgM monoclonal gammopathy of undetermined significance. Haematologica 102, 2077\u20132085 (2017).","journal-title":"Haematologica"},{"key":"277_CR16","doi-asserted-by":"publisher","DOI":"10.1038\/bcj.2017.72","volume":"7","author":"C Jim\u00e9nez","year":"2017","unstructured":"Jim\u00e9nez, C. et al. From Waldenstr\u00f6m\u2019s macroglobulinemia to aggressive diffuse large B-cell lymphoma: a whole-exome analysis of abnormalities leading to transformation. Blood Cancer J. 7, e591 (2017).","journal-title":"Blood Cancer J."},{"key":"277_CR17","doi-asserted-by":"publisher","first-page":"1116","DOI":"10.1038\/leu.2016.8","volume":"30","author":"KV Argyropoulos","year":"2016","unstructured":"Argyropoulos, K. V. et al. Clonal B cells in Waldenstrom\u2019s macroglobulinemia exhibit functional features of chronic active B-cell receptor signaling. Leukemia 30, 1116\u20131125 (2016).","journal-title":"Leukemia"},{"key":"277_CR18","doi-asserted-by":"publisher","first-page":"2370","DOI":"10.1182\/blood-2014-09-602565","volume":"125","author":"B Paiva","year":"2015","unstructured":"Paiva, B. et al. The cellular origin and malignant transformation of Waldenstrom macroglobulinemia. Blood 125, 2370\u20132380 (2015).","journal-title":"Blood"},{"key":"277_CR19","doi-asserted-by":"publisher","first-page":"88","DOI":"10.1038\/nature08638","volume":"463","author":"RE Davies","year":"2010","unstructured":"Davies, R. E. et al. Chronic active B-cell-receptor signalling in diffuse large B-cell lymphoma. Nature 463, 88\u201392 (2010).","journal-title":"Nature"},{"key":"277_CR20","doi-asserted-by":"publisher","first-page":"2538","DOI":"10.1158\/1078-0432.CCR-14-1462","volume":"21","author":"I Kuiatse","year":"2015","unstructured":"Kuiatse, I. et al. Targeting the spleen tyrosine kinase with fostamatinib as a strategy against Waldenstr\u00f6m macroglobulinemia. Clin. Cancer Res. 21, 2538\u20132545 (2015).","journal-title":"Clin. Cancer Res."},{"key":"277_CR21","doi-asserted-by":"publisher","first-page":"78","DOI":"10.1111\/bcp.12048","volume":"76","author":"M Baluom","year":"2013","unstructured":"Baluom, M., Grossbard, E. B., Mant, T. & Lau, D. T. W. Pharmacokinetics of fostamatinib, a spleen tyrosine kinase (SYK) inhibitor, in healthy human subjects following single and multiple oral dosing in three phase I studies. Br. J. Clin. Pharmacol. 76, 78\u201388 (2013).","journal-title":"Br. J. Clin. Pharmacol."},{"key":"277_CR22","doi-asserted-by":"publisher","first-page":"2336","DOI":"10.1182\/blood-2014-08-595934","volume":"125","author":"J Sharman","year":"2015","unstructured":"Sharman, J. et al. An open-label phase 2 trial of entospletinib (GS-9973), a selective spleen tyrosine kinase inhibitor, in chronic lymphocytic leukemia. Blood 125, 2336\u20132343 (2015).","journal-title":"Blood"},{"key":"277_CR23","doi-asserted-by":"publisher","first-page":"2051","DOI":"10.1182\/blood-2012-09-454355","volume":"121","author":"L Xu","year":"2013","unstructured":"Xu, L. et al. MYD88 L265P in Waldenstrom macroglobulinemia, immunoglobulin M monoclonal gammopathy, and other B-cell lymphoproliferative disorders using conventional and quantitative allele-specific polymerase chain reaction. Blood 121, 2051\u20132058 (2013).","journal-title":"Blood"},{"key":"277_CR24","doi-asserted-by":"publisher","first-page":"440","DOI":"10.1158\/0008-5472.CAN-09-1947","volume":"70","author":"TC Chou","year":"2010","unstructured":"Chou, T. C. Drug combination studies and their synergy quantification using the Chou-Talalay method. Cancer Res. 70, 440\u2013446 (2010).","journal-title":"Cancer Res."},{"key":"277_CR25","doi-asserted-by":"crossref","unstructured":"Ramanathan, S., DiPaolo, J. A., Doan, T. & Burge, D. Single and multiple dose-ranging evaluation of safety, pharmacokinetics, and pharmacodynamics of GS-9973, a novel pSYK inhibitor. Cancer Res. 73, 32 (2013).","DOI":"10.1158\/1538-7445.AM2013-32"},{"key":"277_CR26","doi-asserted-by":"publisher","first-page":"387","DOI":"10.1038\/s41586-018-0290-0","volume":"560","author":"JD Phelan","year":"2018","unstructured":"Phelan, J. D. et al. A multiprotein supercomplex controlling oncogenic signaling in lymphoma. Nature 560, 387\u2013391 (2018).","journal-title":"Nature"},{"key":"277_CR27","doi-asserted-by":"publisher","first-page":"2578","DOI":"10.1182\/blood-2009-08-236471","volume":"115","author":"JW Friedberg","year":"2010","unstructured":"Friedberg, J. W. et al. Inhibition of SYK with fostamatinib disodium has significant clinical activity in non-Hodgkin lymphoma and chronic lymphocytic leukemia. Blood 115, 2578\u20132585 (2010).","journal-title":"Blood"},{"key":"277_CR28","doi-asserted-by":"publisher","first-page":"1545","DOI":"10.1182\/blood.V126.23.1545.1545","volume":"126","author":"JP Sharman","year":"2015","unstructured":"Sharman, J. P. et al. Phase 2 trial of entospletinib (GS-9973), a selective Syk inhibitor, in indolent non-Hodgkin\u2019s lymphoma (iNHL). Blood 126, 1545 (2015).","journal-title":"Blood"},{"key":"277_CR29","doi-asserted-by":"publisher","first-page":"624","DOI":"10.1182\/blood.V128.22.624.624","volume":"128","author":"JB Kaplan","year":"2016","unstructured":"Kaplan, J. B. et al. Updated results from a Phase 1 study of TAK-659, an investigational and reversible SYK inhibitor, in patients with advanced solid tumor or lymphoma malignancies. Blood 128, 624 (2016).","journal-title":"Blood"},{"key":"277_CR30","doi-asserted-by":"publisher","first-page":"5324","DOI":"10.1182\/blood-2018-99-111648","volume":"132","author":"J Zhu","year":"2018","unstructured":"Zhu, J. et al. Preliminary results from a phase 1 study of HMPL-523, a highly selective Syk inhibitor, in Chinese patients with mature B-cell lymphomas. Blood 132, 5324 (2018).","journal-title":"Blood"}],"container-title":["Blood Cancer Journal"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41408-020-0277-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41408-020-0277-6","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41408-020-0277-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,12,5]],"date-time":"2022-12-05T14:24:39Z","timestamp":1670250279000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41408-020-0277-6"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,1,31]]},"references-count":30,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2020,1]]}},"alternative-id":["277"],"URL":"https:\/\/doi.org\/10.1038\/s41408-020-0277-6","relation":{},"ISSN":["2044-5385"],"issn-type":[{"value":"2044-5385","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,1,31]]},"assertion":[{"value":"26 August 2019","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"30 December 2019","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"13 January 2020","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"31 January 2020","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"S.T., Z.R.H., M.L.P., J.J.C., and G.Y. have received research funding, consulting fees, and\/or honoraria from Pharmacyclics Inc., and Janssen Oncology Inc.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}],"article-number":"12"}}